Cargando…

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

PURPOSE: S-1 is a standard postoperative adjuvant chemotherapy for patients with stage II or III gastric cancer in Asia. Neoadjuvant or perioperative strategies dominate in Western countries, and docetaxel has recently shown significant survival benefits when combined with other standard regimens in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Kazuhiro, Kodera, Yasuhiro, Kochi, Mitsugu, Ichikawa, Wataru, Kakeji, Yoshihiro, Sano, Takeshi, Nagao, Narutoshi, Takahashi, Masazumi, Takagane, Akinori, Watanabe, Takuya, Kaji, Masahide, Okitsu, Hiroshi, Nomura, Takashi, Matsui, Takanori, Yoshikawa, Takaki, Matsuyama, Jin, Yamada, Makoto, Ito, Seiji, Takeuchi, Masahiro, Fujii, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524985/ https://www.ncbi.nlm.nih.gov/pubmed/30925125 http://dx.doi.org/10.1200/JCO.18.01138

Ejemplares similares

Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study
por: Kodera, Yasuhiro, et al.
Publicado: (2023)

(18)F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12)
por: Nakamura, Masato, et al.
Publicado: (2021)

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
por: Masuishi, Toshiki, et al.
Publicado: (2020)

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11
por: Satake, Hironaga, et al.
Publicado: (2018)

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11
por: Satake, Hironaga, et al.
Publicado: (2018)

Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)
por: Kimura, Yutaka, et al.
Publicado: (2017)

Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study
por: Satake, Hironaga, et al.
Publicado: (2018)

Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)
por: Sunakawa, Y., et al.
Publicado: (2022)

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
por: Tebbutt, Niall C, et al.
Publicado: (2016)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
por: Yi, J H, et al.
Publicado: (2012)

Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial)
por: Tanigawa, Nobuhiko, et al.
Publicado: (2015)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
por: Yasui, H., et al.
Publicado: (2023)

Simultaneous occurrence of distant metastases to the small intestine and the thoracic esophagus from anaplastic thyroid carcinoma: a case report
por: Kobayashi, Makoto, et al.
Publicado: (2015)

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials
por: Sebio, A., et al.
Publicado: (2016)

Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
por: Shiga, Taro, et al.
Publicado: (2020)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
por: Cucciniello, Linda, et al.
Publicado: (2022)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer
por: Oki, Yasunari, et al.
Publicado: (2010)

ACT-07 Clinical Trials of 11C-Methionine PET for brain tumors
por: Yamaguchi, Shigeru, et al.
Publicado: (2020)

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
por: Kim, Seung Tae, et al.
Publicado: (2022)

Antitumor Activity of Fluoropyrimidines and Thymidylate Synthetase Inhibition
por: Kubota, Tetsuro, et al.
Publicado: (1991)

Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management
por: Jurczyk, Michał, et al.
Publicado: (2021)

Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study
por: Maeda, Osamu, et al.
Publicado: (2017)

A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
por: Hasegawa, Hirotaka, et al.
Publicado: (2022)

A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment
por: Deac, Andrada-Larisa, et al.
Publicado: (2020)

Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
por: Grumetti, Laura, et al.
Publicado: (2022)

Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials
por: Tian, Wei, et al.
Publicado: (2023)

EXM 92-07 07/05/92
por: Daems, G
Publicado: (1992)

Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis
por: Marchetti, S, et al.
Publicado: (2001)

A narrative review of genetic factors affecting fluoropyrimidine toxicity
por: Gmeiner, William H.
Publicado: (2021)

Mutual induced-fit mechanism drives binding between intrinsically disordered Bim and cryptic binding site of Bcl-xL
por: Bekker, Gert-Jan, et al.
Publicado: (2023)

Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
por: Koizumi, Wasaburo, et al.
Publicado: (2013)

Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer
por: Leonard, R C F
Publicado: (2001)

Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation
por: Milano, G, et al.
Publicado: (2004)

In vivo Antitumor Effects of Fluoropyrimidines on Colon Adenocarcinoma 38 and Enhancement by Leucovorin
por: Iigo, Masaaki, et al.
Publicado: (1992)

TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
por: Petrelli, Fausto, et al.
Publicado: (2016)

DPD status and fluoropyrimidines-based treatment: high activity matters too
por: Chamorey, Emmanuel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7mn4bms9381d713tcsk6ea7g16